Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary fibrosis (IPF) ... In preclinical trials, FS2 ...
Collaboration Expected to AdvanceFS2 Topical Platform and Strengthen BGLC's Biotech Footprint in Asia... We see Birch's FS2 platform as an exciting addition to our growing portfolio in regenerative medicine and precision therapeutics.".
